Background In health economic studies, valid and reliable cost data are essential to reach meaningful conclusions. In the case of multiple sclerosis (MS), such studies are often based on primary data for which the underlying survey instruments have not been published. In addition, heterogeneous methods make the comparability and interpretation of such study results difficult. To standardize health economic studies in MS, the Multiple Sclerosis Health Resource Utilization Survey (MS-HRS) was developed, validated and published in a freely accessible format. Research question This review focuses on the MS-HRS. We report on the methodological background of studies on the assessment of cost of illness as well as MS-HRS-based results on the costs of disease dynamics in people with MS. Methods This article is based on a selective literature review on the MS-HRS as well as on health economic aspects of cost assessment. Results The MS-HRS provides a holistic assessment of direct medical, direct non-medical and indirect resource utilization. Within indirect costs, we considered absenteeism, either short term (sick leave) or long term (disability pension), but also presenteeism, which refers to impaired performance during work. Resources were valued at the societal opportunity cost or the best possible approximation. First analyses based on MS-HRS showed that, in addition to inpatient disease severity and clinical course, disease dynamics in form of relapses and progression have enormous socioeconomic implications. Conclusion Valid cost data bring transparency to the economic consequences of diseases. In addition to clinical data, cost data can be used to determine cost-effectiveness and thus reveal opportunities for more efficient patient care. For the case of MS, a freely accessible tool is available for cost assessments.
|Seiten (von - bis)||42-48|
|Fachzeitschrift||Fortschritte der Neurologie, Psychiatrie|
|Publikationsstatus||Veröffentlicht - Jan. 2022|
Ziele für nachhaltige Entwicklung
- Real world evidence, Multiple sclerosis, Cost of illness, Health economics, MS-HRS, Cost of illness, Health economics, MS-HRS, Multiple sclerosis, Real world evidence